Gyula Acsadi
Neurology with Special Qualifications in Child Neurology · Detroit, MINPI 1740227347
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (42.1%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 12 manufacturers reported payments, led by Biogen at 52.9% of the total. Reporting peaked in 2019 at $47,927 and has fallen 99.7% since, to $154 in 2025. Among neurology with special qualifications in child neurology clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 92 payments — averaging $930.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biogen$45K
- Sarepta Therapeutics, Inc.$19K
- Novartis Gene Therapies, Inc. (fka Avexis, Inc.)$13K
- Genentech, Inc.$8K
- Biomarin Pharmaceutical Inc.$143
- SK Life Science, Inc.$142
- plus $284 from 6 others
Across 128 payments — averaging $7369.87 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Biogen$431K
- Sarepta Therapeutics, Inc.$367K
- Novartis$74K
- Novartis Gene Therapies, Inc. (fka Avexis, Inc.)$42K
- ITF Therapeutics LLC$29K
What the payments were for
- Consulting fees$36,02042%
- Speaking & faculty fees$35,53242%
- Travel & lodging$11,46313%
- Food & beverage$2,4453%
- Education$1470%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biogen | 38 | $45,260 |
| Sarepta Therapeutics, Inc. | 16 | $18,643 |
| Novartis Gene Therapies, Inc. (fka Avexis, Inc.) | 15 | $12,739 |
| Genentech, Inc. | 7 | $8,396 |
| Biomarin Pharmaceutical Inc. | 2 | $143 |
| SK Life Science, Inc. | 3 | $142 |
| ITF Therapeutics LLC | 1 | $88 |
| Neurelis, Inc. | 2 | $75 |
| PTC Therapeutics, Inc. | 2 | $49 |
| Novartis | 2 | $39 |
| NS Pharma, Inc. | 1 | $27 |
| Travere Therapeutics, Inc. | 3 | $6 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SPINRAZA$42,121
- Exondys 51$13,409
- ZOLGENSMA$9,333
- Non-Covered Product$8,258
- Skyclarys$800
- Zurzuvae$800
How this compares
$85,606 in reported general payments places this provider in the 95th percentile of 62 neurology with special qualifications in child neurology providers in Michigan.
See all neurology with special qualifications in child neurology providers in Michigan →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EvrysdiRisdiplam | 15 | $446,789 |
Paid to pharmacies, not to this prescriber.
Other neurology with special qualifications in child neurology in Detroit
- Michelle FigueroaDetroit$57K
- Aimee LuatDetroit$12K
- Eishi AsanoDetroit$5K
- Jayaprakash GosalakkalDetroit$3K
- Daniela TaposDetroit$3K
- Beata RuprechtDetroit$2K
- Carla WatsonDetroit$1K
- Naznin MahmoodDetroit$972
- Fatema SerajeeDetroit$910
- Amanda WeberDetroit$772
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.